Breaking News Instant updates and real-time market news.

BABA

Alibaba

$161.94

-6.315 (-3.75%)

, WMT

Walmart

$117.56

0.34 (0.29%)

06:18
10/09/19
10/09
06:18
10/09/19
06:18

Alibaba to stop selling e-cigarette components in the U.S., Reuters reports

Alibaba (BABA) will stop selling e-cigarette components in the U.S. amid growing regulatory scrutiny and reports of lung disease and some deaths linked to vaping, Reuters' Josh Horwitz reports. Alibaba's move follows announcements this week by Kroger (KR) and Walgreens Boots Alliance (WBA) that they will stop selling e-cigarettes at their stores, in line with a similar decision by Walmart (WMT). Publicly traded companies in the space include Altria Group (MO), British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM). Reference Link

BABA

Alibaba

$161.94

-6.315 (-3.75%)

WMT

Walmart

$117.56

0.34 (0.29%)

KR

Kroger

$24.46

-0.37 (-1.49%)

WBA

Walgreens Boots Alliance

$52.09

-0.66 (-1.25%)

MO

Altria Group

$42.02

-0.03 (-0.07%)

BTI

British American Tobacco

$34.36

-0.385 (-1.11%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$76.36

-0.84 (-1.09%)

  • 09

    Oct

  • 28

    Oct

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

BABA Alibaba
$161.94

-6.315 (-3.75%)

09/06/19
SBSH
09/06/19
NO CHANGE
Target $326
SBSH
Buy
NetEase price target raised to $326 from $301 at Citi
Citi analyst Hillman Chan raised his price target for NetEase (NTES) to $326 from $301 saying he's positive on the sale of Kaola to Alibaba (BABA). The disposal signals NetEase's continuous focus on profitability and the additional funding to Cloud Music could make it more competitive versus Tencent Music (TME), Chan tells investors in a research note. The analyst expects investors to gradually assign value to NetEase's remaining non-gaming assets, like Cloud Music, and he keeps a Buy rating on the shares.
09/10/19
BOFA
09/10/19
NO CHANGE
Target $39
BOFA
Buy
Easing competition presents potential upside for Pinduoduo, says BofA/Merrill
BofA Merrill Lynch analyst Joyce Ju said her proprietary price point checks on some products across Chinese e-commerce platforms, including Alibaba's (BABA) Taobao, support the assumption of a stabilized competitive landscape and less aggressive promotion in Q3. The easing price competition should give Pinduoduo (PDD) more budget flexibility and room for moderate margin upside in non-peak season, according to Ju, who raised her price target on the stock to $39 from $34. She maintains a Buy rating on Pinduoduo.
09/16/19
SBSH
09/16/19
NO CHANGE
Target $233
SBSH
Buy
Alibaba unlikely to revise sales guidance at investor day, says Citi
Citi analyst Alicia Yap expects Alibaba's September 23 and 24 investor days to focus on new chairman and CEO Daniel Zhang's vision and strategy, the CFO's comments on investment strategy and margins, and progress and customer feedback on recommended feeds and Tmall 2.0 initiatives. The analyst believes the CFO is unlikely to revise Alibaba's fiscal 2020 revenue guidance, and instead will likely offer reassurance on "healthy" growth in core marketplace margins and on a disciplined approach to new investment initiatives. Yap keeps a Buy rating on Alibaba shares with a $233 price target.
10/04/19
HSBC
10/04/19
NO CHANGE
Target $233
HSBC
Buy
HSBC boosts Alibaba target to $233 on continued dominance in retail market
After hosting a dinner with an apparel brand expert, HSBC analyst Binnie Wong says Alibaba (BABA) "remains dominant." Alibaba is still leading the way in the brands' online retail market, Wong tells investors in a research note. Further, Tmall is more effective in new products launches, with higher profits for Alibaba versus Pinduoduo (PDD), contends the analyst. Wong views Alibaba as attractively valued and boosted the stock's price target to $233 from $230. The analyst keeps a Buy rating on the shares.
WMT Walmart
$117.56

0.34 (0.29%)

09/05/19
MSCO
09/05/19
NO CHANGE
Target $125
MSCO
Overweight
Walmart price target raised to $125 from $115 at Morgan Stanley
Morgan Stanley analyst Simeon Gutman said PhonePe wasn't on investors' radar when Walmart took a majority stake in Flipkart last year, but now the payments processor is coming into focus. Flipkart's PhonePe could be an Indian "Super App" worth from $7B to as much as $20B in a bull case, estimated Gutman, who now believes a sum-of-the-parts analysis is the best way to value Walmart's "disparate segments." He increased his price target on Walmart shares to $125 from $115 and raised his Bull Case valuation on the stock to $165 from $150. Gutman keeps an Overweight rating on Walmart.
09/23/19
BARD
09/23/19
NO CHANGE
Target $130
BARD
Outperform
Walmart price target raised to $130 from $120 at Baird
Baird analyst Peter Benedict raised his price target on Walmart to $130 from $120 following meetings with management. The meetings were upbeat as efforts to transform its core retail capabilities and culture are gaining traction with consumers which is fueling an evolving market perception of the company. Benedict reiterated his Outperform rating on Walmart shares.
09/18/19
SBSH
09/18/19
NO CHANGE
Target $135
SBSH
Buy
Walmart price target raised to $135 from $129 at Citi
Citi analyst Gregory Badishkanian raised his price target for Walmart (WMT) to $135 from $129 after taking over coverage of the name. The analyst keeps a Buy rating on the shares. An aggressive omni-channel strategy, low-prices, grocery offerings, and productivity initiatives should drive long-term sales growth and margin upside, Badishkanian tells investors in a research note. The analyst also took over coverage of BJ's Wholesale (BJ) with an unchanged Buy rating and $32 price target, as well as Costco Wholesale (COST) with an unchanged Neutral rating and price target of $303, up from $281.
09/30/19
WELS
09/30/19
NO CHANGE
Target $30
WELS
Outperform
National Vision price target lowered to $30 from $37 at Wells Fargo
Wells Fargo analyst Zachary Fadem lowered his price target for National Vision (EYE) to $30 from $37 giving near-term overhangs. The analyst also notes that sentiment is "increasingly poor," but margin improvement offers a chance at redemption. While investor sentiment around Walmart (WMT) has shifted from an opportunity to an overhang, Fadem believes shares now price a worst case scenario that he views unlikely near-term. He reiterates an Outperform rating on National Vision's stock.
KR Kroger
$24.46

-0.37 (-1.49%)

09/13/19
MSCO
09/13/19
NO CHANGE
Target $26
MSCO
Equal Weight
Morgan Stanley says Kroger pulling 2020 guidance underscores industry challenges
Morgan Stanley analyst Simeon Gutman does not view Kroger pulling its previous 2020 guidance as a surprise, stating that this underscores industry challenges that he does not believe are likely to abate. While he sees limited signs of a core sales and profit inflection at Kroger, he also views the stock's valuation as "undemanding," which along with stabilizing trends should limit the stock's downside. Gutman maintains an Equal Weight rating and $26 price target on Kroger following the company's "fine" Q2 results.
09/13/19
FBCO
09/13/19
NO CHANGE
Target $29
FBCO
Outperform
Kroger price target raised to $29 from $27 at Credit Suisse
Credit Suisse analyst Judah Frommer reiterated an Outperform rating on Kroger and raised his price target to $29, saying the Q2 earnings represent its most compelling quarterly results since the introduction of the company's Restock Kroger plan. Overall, Frommer tells investors in a research note that he feels management's decision to pull its 2020 guidance was a proactive "clearing of the decks" for a November 5 Investor Day that can now focus on the drivers of core business stabilization and a continued ramp in alternative profits.
08/02/19
08/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FMC Corporation (FMC) upgraded to Buy from Neutral at Goldman Sachs with analyst Adam Samuelson saying he views FMC as a as "unique crop protection pure-play" with favorable growth prospects related to its diamides business and a "healthy" pipeline of crop protection active ingredients. 2. Pinterest (PINS) upgraded to Buy from Hold at Deutsche Bank with analyst Lloyd Walmsley saying he raised his estimates meaningfully following last night's Q2 results on more confidence that the company can scale its ad business, in the U.S. and internationally, faster than expected. 3. Westpac Banking (WBK) upgraded to Equal Weight from Underweight at Morgan Stanley. 4. Kroger (KR) upgraded to Buy from Hold at Pivotal Research with analyst Ajay Jain saying despite a lack of near-term catalysts, Kroger shares are "simply mispriced at this time." 5. SurveyMonkey (SVMK) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying the company's execution points towards "strong" compounding growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/19
BMOC
09/04/19
NO CHANGE
Target $26
BMOC
Market Perform
Kroger price target raised to $26 from $24 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Kroger to $26 to reflect the findings of her broader "Food Retail Roundup" note, showing that while August was not as strong as July, it still marked a good month of grocery sales in the U.S. The analyst notes that monthly sales came in ahead of their 6- and 12-month averages, suggesting that the quarter-to-date momentum for food retailers is "solid". Bania still keeps her Market Perform rating on Kroger, citing her expectations of "benign" food inflation outlook and longer term risks related to Ocado.
WBA Walgreens Boots Alliance
$52.09

-0.66 (-1.25%)

09/11/19
DBAB
09/11/19
INITIATION
Target $53
DBAB
Sell
Walgreens Boots Alliance initiated with a Sell at Deutsche Bank
Deutsche Bank analyst George Hill initiated Walgreens Boots Alliance with a Sell rating and a price target of $53 as part of a broader research note on Healthcare Technology & Services. The analyst warns that the company's stand-alone pharmacy business strategy will face "unrelenting competitive and reimbursement pressure", which will likely yield negative earnings revisions. Hill adds that the current "punitive" multiple on the stock is warranted.
09/27/19
RBCM
09/27/19
INITIATION
Target $59
RBCM
Sector Perform
Walgreens Boots Alliance assumed with a Sector Perform at RBC Capital
RBC Capital analyst Anton Hie assumed coverage of Walgreens Boots Alliance with a Sector Perform rating and a price target of $59. The analyst is positive on the company's "strong national presence" and sees its efforts to leveraged its partners' expertise to broaden its capabilities as a smart move. However, Hie does not expect Walgreens shares to reach "significantly higher" multiples until the management offers a more specific strategic direction and evidence of "strong progress" with a higher earnings trajectory.
07/31/19
PIPR
07/31/19
NO CHANGE
Target $182
PIPR
Overweight
DexCom price target raised to $182 from $173 at Piper Jaffray
Piper Jaffray analyst JP Kim raised his price target on DexCom (DXCM) to $182 and kept his Overweight rating after its "solid" Q2 results and raised guidance. driven by the 41% U.S. revenue growth in spite of the tougher comp. The analyst is positive on the pharmacy coverage unlocking more type 2 diabetes patients, manufacturing lines preparing for the G7 Continuous Glucose Monitoring system, and its "direct to Apple (AAPL) Watch"compatibility, as well as the company's Walgreens (WBA) partnership, even though he sees tougher annual comps and a Medicare pricing headwind in Q4.
06/28/19
06/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating. 2. Biogen (BIIB) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term." 3. Live Nation (LYV) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying he still likes the company's growth prospects and "consistent" operating performance. 4. Arrowhead (ARWR) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Elemer Piros saying he views the stock as fairly valued. 5. Darden (DRI) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MO Altria Group
$42.02

-0.03 (-0.07%)

09/24/19
MSCO
09/24/19
NO CHANGE
Target $44
MSCO
Equal Weight
Altria could rise 20%+ if deal an acquisition, not merger, says Morgan Stanley
Morgan Stanley analyst Pamela Kaufman said she expects Philip Morris (PM) and Altria Group (MO) to announce the outcome of their merger talks in the coming weeks. If the deal is confirmed as an all-stock merger of equals consistent with media reports, which she attributes a 70% probability of happening, than she expects Altria shares to be flat at about $41 per share. In a scenario where the companies end talks to merge without a deal, Kaufman sees Altria shares rising about 8% as she calculates a $44 price target for the standalone business assuming its stake in Juul is worth $8.5B, or about two-thirds of the price paid. She sees 20% odds of this scenario. In a third scenario, a deal is financed through a combination of debt and equity. She believes Philip Morris could pay $50 per share for Altria and generate 18%-20% EPS accretion by 2022. In that last scenario, she sees 22% upside potential for Altria shares, though Kaufman only gives such a deal a 10% chance of happening. Kaufman maintains an Equal Weight rating with a $44 price target on Altria shares.
09/26/19
WELS
09/26/19
NO CHANGE
WELS
Wells Fargo not surprised Philip Morris, Altria Group ended merger talks
Wells Fargo analyst Bonnie Herzog says that while she is dismayed by the announcement that Philip Morris (PM) and Altria (MO) have ended merger talks, she is not all that surprised given the length of negotiations and the litany of negative FDA/health headlines throughout. The analyst expects the stocks to trade up sharply since "clearly the market wasn't in favor of this combination." Herzog adds that it appears to her the talks fell apart over JUUL and the companies announced they have agreed to focus on launching iQOS in the U.S. "as part of their mutual interest to achieve a smoke free future." The analyst continues to believe Philip Morris/Altria have a competitive advantage, especially in this environment, with iQOS. She continues to "strongly recommend" both stocks, with Philip Morris remaining her top stock pick.
10/07/19
WELS
10/07/19
NO CHANGE
WELS
Outperform
Altria Group's competitive moat widens with iQOS, says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterates an Outperform rating on Altria Group following her private tour of the new iQOS store/formats that launched in Atlanta. The analyst says that her discussions with the company's management reinforced her belief that iQOS holds a distinct competitive advantage in the U.S. given it's the only RRP authorized by the FDA that will also be allowed to sell mint/menthol flavors in the event the FDA clears the market of non-tobacco flavor variants. While it is hard to say how long it could take others to win FDA authorization, given it took iQOS about two years, Herzog believes the FDA's standard is high. As such, she sees the removal of e-cigarette flavors only widening iQOS' competitive moat.
10/01/19
BOFA
10/01/19
UPGRADE
Target $96
BOFA
Buy
Philip Morris upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Lisa Lewandowski upgraded Philip Morris (PM) to Buy with a price target of $96 after the suspended merger discussions with Altria (MO) amid the heightened risk for U.S. vaping category following reports of lung health concerns. The analyst notes that the whole industry may be impacted by uncertainty around vaping, but she sees Philip Morris rising above the "noise" due to its lack of vaping exposure, strong underlying fundamentals, and potential for offering alternatives to vaping products.
BTI British American Tobacco
$34.36

-0.385 (-1.11%)

08/27/19
SBSH
08/27/19
NO CHANGE
SBSH
Citi sees no antitrust reason to stop Philip Morris, Altria deal
Citi analyst Adam Spielman is surprised by the merger talks between Philip Morris (MO) and Altria Group (MO) but feels the deal is likely to go ahead as he sees no antitrust reason to stop it. With the combined company likely a stronger competitor, the potential deal is not a positive for both British American Tobacco (BTI) and Imperial Brands (IMBBY), Spielman tells investors in a research note.
09/12/19
SBSH
09/12/19
NO CHANGE
SBSH
E-vapor regulation to hit Juul hard, 'odd time' for merger talks, says Citi
The Trump Administration said yesterday that it will "clear" the market of all non-tobacco flavored e-vapor products, including mint and menthol, Citi analyst Adam Spielman tells investors in a research note. The analyst had hoped the rules would have little impact on Juul as it has stopped supplying fruit flavors to physical stores. However, Trump's proposal is likely to hit Juul hard, as about three-quarter of its volume is in mint, says Spielman. Further, he believes at least half of British American Tobacco's (BTI) and IImperial Brands' (IMBBY) e-vapor volumes in the U.S. will be banned under the new definition. This all reinforces that this is an "odd time" for Philip Morris (PM) and Altria Group (MO) to be in merger talks, contends Spielman. The analyst, who doubts Trump's announcement will affect the talks between the companies, says the future of tobacco regulation in the U.S. is unclear currently. "We can only assume the companies have chosen to talk now because they are very confident about the outcomes. We, by contrast, see plenty of risk," writes Spielman.
07/16/19
WELS
07/16/19
NO CHANGE
WELS
Wells says Nielsen restatement could be positive for Monster, tobacco stocks
Wells Fargo analyst Bonnie Herzog noted that Nielsen (NLSN) just announced that it will restate data to address serious issues with its calculation methodology in the convenience store channel related to projections it applied to independent c-stores. The restated data, to be released on August 20, is expected to improve cigarette and energy drink trends and she views this as a positive for tobacco stocks and Monster Beverage (MNST). Publicly traded companies in the tobacco space include Altria Group (MO), British American Tobacco (BTI) and Philip Morris (PM).
08/28/19
JPMS
08/28/19
NO CHANGE
JPMS
Neutral
Philip Morris selloff on Altria merger talks overdone, says JPMorgan
JPMorgan analyst Celine Pannuti views the selloff in shares of Philip Morris (PM) following confirmation of the company's merger talks with Altria Group (MO) as overdone. The deal leads to value accretion at no premium and U.S. regulatory risks are already embedded in the sector de-rating, Pannuti tells investors in a research note. The analyst also sees the weakness in British American Tobacco (BTI) shares as a buying opportunity. The consideration of a merger between Philip Morris and Altria is a vote of confidence in the U.S. combustibles profit pool, contrary to current market sentiment, says Pannuti. The analyst keeps a Neutral rating on Philip Morris with an $86 price target.
IMBBY Imperial Brands
$0.00

(0.00%)

05/28/19
SBSH
05/28/19
NO CHANGE
SBSH
Cigarette data from Nielsen 'dire,' industry data also 'very bad,' says Citi
Citi analyst Adam Spielman noted that Nielsen reported earlier today that cigarette industry volumes fell 11.2% in the four weeks ended May 18, noting that shares of Altria (MO), British American Tobacco (BTI) and Imperial (IMBBY) all fell following the "dire" data. Volumes in MSAi, the industry database that he regards as much more reliable than Nielsen, were down 6.4% in the same period, which Spielman said "is still a very bad figure, but it is a lot, lot better than the Nielsen one." Looking ahead, the analyst said he expects "gradually less bad" volumes in Nielsen in the rest of the year, though he noted that Altria has said it expects industry volumes to fall about 4%-5% this year and he forecasts a decline of about 6%. In late afternoon trading, Altria shares are down 4.5%, British American has declined over 4% and Philip Morris (PM) is down 5%.
03/28/19
SBSH
03/28/19
UPGRADE
SBSH
Buy
Imperial Brands upgraded to Buy from Neutral at Citi
Citi analyst Adam Spielman upgraded Imperial Brands to Buy from Neutral and raised his price target for the shares to GBP 30 from GBP 27. The analyst believes organic revenue growth for tobacco companies will pick up this year as sales of next generation products accelerate. Further, the regulatory threat will probably move away from cigarettes, Spielman tells investors in a research note. He thinks an even greater focus on e-vapor cigarettes could be positive for both British American Tobacco and Imperial Brands.
PM Philip Morris
$76.36

-0.84 (-1.09%)

10/01/19
10/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ericsson (ERIC) upgraded to Buy from Hold at Canaccord with analyst Michael Walkley saying since the Q2 earnings report, Ericsson has announced deals with Nex-Tech, RINA, and KDDI, demonstrating continuing 5G momentum. 2. VMware (VMW) upgraded to Outperform from Market Perform at Wells Fargo with analyst Philip Winslow saying investors have been concerned that growing interest in deploying containerized applications into Kubernetes-centric environments will eventually reduce customer demand for VMware's virtualization-centric product portfolio. 3. Tradeweb Markets (TW) upgraded to Overweight from Equal Weight at Barclays with analyst Jeremy Campbell saying recent weakness in the shares "seems largely technical," which presents an "attractive upside opportunity." 4. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underperform at BofA/Merrill with analyst Christopher Carey saying the bar on the company's earnings consensus may be "too low." 5. Philip Morris (PM) upgraded to Buy from Neutral at BofA/Merrill with analyst Lisa Lewandowski citing the suspended merger discussions with Altria (MO) amid the heightened risk for U.S. vaping category following reports of lung health concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/19
BOFA
10/01/19
UPGRADE
BOFA
Buy
Philip Morris upgraded to Buy from Neutral at BofA/Merrill

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

, SPX

S&P 500

$0.00

(0.00%)

20:46
10/15/19
10/15
20:46
10/15/19
20:46
Periodicals
China may retaliate if U.S. Congress passes bill supporting Hong Kong protesters 

Report from Bloomberg.

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.74

0.59 (2.02%)

, ABT

Abbott

$82.06

2.25 (2.82%)

20:25
10/15/19
10/15
20:25
10/15/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$29.74

0.59 (2.02%)

ABT

Abbott

$82.06

2.25 (2.82%)

USB

U.S. Bancorp

$53.73

0.47 (0.88%)

PNC

PNC Financial

$141.86

1.38 (0.98%)

BK

BNY Mellon

$44.37

0.47 (1.07%)

ALLY

Ally Financial

$32.03

0.68 (2.17%)

CMA

Comerica

$67.01

1.765 (2.71%)

FHN

First Horizon

$16.13

0.22 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

  • 07

    Nov

  • 12

    Nov

RIO

Rio Tinto

$51.40

-0.43 (-0.83%)

20:17
10/15/19
10/15
20:17
10/15/19
20:17
Hot Stocks
Rio Tinto reports Q3 Pilbara iron ore output 87.3M tons, up 6% from last year »

Reports Q3 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNTX

Gentex

$26.98

0.65 (2.47%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Gentex initiated  »

Gentex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 04

    Nov

VNE

Veoneer

$16.11

0.82 (5.36%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Veoneer initiated  »

Veoneer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VC

Visteon

$82.45

0.63 (0.77%)

20:15
10/15/19
10/15
20:15
10/15/19
20:15
Initiation
Visteon initiated at Guggenheim »

Visteon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

DLPH

Delphi Technologies

$14.37

0.45 (3.23%)

20:14
10/15/19
10/15
20:14
10/15/19
20:14
Initiation
Delphi Technologies initiated at Guggenheim »

Delphi Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

BWA

BorgWarner

$37.74

0.68 (1.83%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
BorgWarner initiated at Guggenheim »

BorgWarner initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

LEA

Lear

$121.75

3.94 (3.34%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
Lear initiated at Guggenheim »

Lear initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 04

    Nov

  • 10

    Dec

  • 11

    Dec

DFIN

Donnelley Financial Solutions

$10.54

0.035 (0.33%)

20:12
10/15/19
10/15
20:12
10/15/19
20:12
Initiation
Donnelley Financial Solutions initiated at B. Riley FBR »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

, TEVA

Teva

$6.96

0.22 (3.26%)

19:17
10/15/19
10/15
19:17
10/15/19
19:17
Periodicals
As part of proposed settlement, Teva offers $15B of free drugs, Bloomberg says »

The report also notes…

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

TEVA

Teva

$6.96

0.22 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 07

    Nov

WAFD

Washington Federal

$36.81

0.15 (0.41%)

19:04
10/15/19
10/15
19:04
10/15/19
19:04
Earnings
Washington Federal reports Q4 EPS 66c, consensus 65c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

INGR

Ingredion

$81.17

0.94 (1.17%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Hot Stocks
Ingredion discloses malware affecting certain data centers »

Ingredion issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Periodicals
Pelosi holds off on House vote over impeachment inquiry, Politico says »

House Speaker Nancy…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.40

0.02 (0.14%)

18:59
10/15/19
10/15
18:59
10/15/19
18:59
Hot Stocks
Petrobras signs charter contracts for two FPSO platforms »

Petrobras announced that …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SNBR

Sleep Number

$46.69

0.48 (1.04%)

, UAL

United Airlines

$87.90

0.9 (1.03%)

18:58
10/15/19
10/15
18:58
10/15/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sleep…

SNBR

Sleep Number

$46.69

0.48 (1.04%)

UAL

United Airlines

$87.90

0.9 (1.03%)

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

FULT

Fulton Financial

$15.90

0.19 (1.21%)

ETN

Eaton

$82.16

1.29 (1.60%)

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

MGM

MGM Resorts

$27.87

-0.1 (-0.36%)

JBHT

J.B. Hunt

$111.65

1.985 (1.81%)

IBKR

Interactive Brokers

$47.43

0.26 (0.55%)

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

NTRA

Natera

$39.21

1.01 (2.64%)

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

X

U.S. Steel

$11.43

0.27 (2.42%)

ARCE

Arco Platform

$48.15

0.75 (1.58%)

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 18

    Oct

KKR

KKR

$26.79

0.67 (2.57%)

, DB

Deutsche Bank

$7.79

0.235 (3.11%)

18:21
10/15/19
10/15
18:21
10/15/19
18:21
Periodicals
KKR, partners cancel Latitude Financial IPO, Reuters reports »

KKR (KKR) and its…

KKR

KKR

$26.79

0.67 (2.57%)

DB

Deutsche Bank

$7.79

0.235 (3.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 29

    Oct

  • 04

    Nov

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:20
10/15/19
10/15
18:20
10/15/19
18:20
Hot Stocks
Breaking Hot Stocks news story on Tradeweb Markets »

Tradeweb Markets sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:17
10/15/19
10/15
18:17
10/15/19
18:17
Syndicate
Tradeweb Markets files to sell 14.8M shares of Class A common stock »

Refinitiv will continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:16
10/15/19
10/15
18:16
10/15/19
18:16
Earnings
Tradeweb Markets sees Q3 adjusted EPS 27c, consensus 25c »

Sees Q3 revenue $200.98M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

EDIT

Editas Medicine

$20.30

0.48 (2.42%)

18:15
10/15/19
10/15
18:15
10/15/19
18:15
Hot Stocks
Editas Medicine, AskBio enter research collaboration over in vivo delivery »

Editas Medicine and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$114.78

2.43 (2.16%)

18:03
10/15/19
10/15
18:03
10/15/19
18:03
Periodicals
NV regulators want to ban Steve Wynn from NV casino industry, Reuters says »

The Nevada Gaming Control…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

18:00
10/15/19
10/15
18:00
10/15/19
18:00
Hot Stocks
Stitch Fix director buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NTRA

Natera

$39.21

1.01 (2.64%)

17:48
10/15/19
10/15
17:48
10/15/19
17:48
Syndicate
Natera files to sell $175M of common stock »

J.P. Morgan, Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$3.36

0.2 (6.33%)

17:45
10/15/19
10/15
17:45
10/15/19
17:45
Earnings
Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.